Anti-LeY-CAR

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-LeY-CAR

Drug Alias NameAnti-LeY-CAR

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionT lymphocyte replacementsLewis-Y antigen modulators

TargetsLewis-Y antigen

Therapy Area/IndicationsMyelodysplastic SyndromesMultiple MyelomaLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPeter Maccallum Cancer Centre

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPeter Maccallum Cancer Centre

Active IndicationsN/A

Inactive IndicationsMyelodysplastic SyndromesMultiple MyelomaLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A